LONDON – GE Healthcare Life Sciences is bringing its heft to 3D bioprinting in an agreement with Advanced Solutions Life Science Inc. (ASLS), in which the partners aim to automate the production of quality-assured, vascularized tissues, for bone, soft tissue and organ replacements.

Boston-based conglomerate GE worked to make the case for its health care business to investors at a Dec. 2 event, but Wall Street seemed underwhelmed. The company’s share price remains hovering around lows not seen since the 2008-2009 financial crisis.